Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Pediatr Blood Cancer. 2021 May;68(Suppl 2):e28473. doi: 10.1002/pbc.28473

Table 3.

International Neuroblastoma Treatment Risk Groups

INRG Stage Age (months) Histological classification Grade of tumor differentiation MYCN 11q Aberration Ploidy Pretreatment risk group
L1/L2 Any GN maturing A Very Low
GNB intermixed
L1 Any Any except NA B Very Low
GN maturing or Amp K High
GNB intermixed
L2 <18 Any except NA No D Low
GN maturing or Yes G
GNB intermixed Intermediate
≥18 GNB nodular; Differentiating NA No E Low
neuroblastoma Poorly differentiating or undifferentiating NA Yes
H Intermediate
M <18 NA Hyperdiploid F Low
<12 NA Diploid I Intermediate
12 to <18 NA Diploid J Intermediate
<18 Amp O High
≥18 P High
MS <18 NA No C Very Low
Yes Q High
Amp R High